HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Study data convince Lundbeck to push new migraine drug forward

A possible alternative to "anti-CGRP" medications, the drug didn't meet some analysts' expectations in mid-stage testing but still convinced Lundbeck to pursue further development.

By BioPharma Dive · Jun 5, 2026 · via BioPharma Dive
Study data convince Lundbeck to push new migraine drug forward

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25
The WeekFiercePharma ↗
Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25
The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 b…
Jun 6, 2026
'It looks like this hypothesis will pan out': Cullinan unveils data building case for autoimmune TCEs
The WeekFierceBiotech ↗
'It looks like this hypothesis will pan out': Cullinan unveils data building case for autoimmune TCEs
When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But an…
Jun 6, 2026
Medicare Advantage 2026: Low Premiums, High Limits, Tight Control
The WeekBriefing
Medicare Advantage 2026: Low Premiums, High Limits, Tight Control
Three-quarters of Medicare Advantage enrollees pay no added premium in 2026, but rising out-of-pocket caps and…
Jun 6, 2026